Document is current
Any future updates will be listed below
-
Authors
Hendek, Hasan Hüseyin
Blusch, Alina
Heitmann, Neele
Oberhagemann, Sarah
Demir, Seray
Pedreiturria, Xiomara
Gold, Ralf
Faissner, Simon
-
Funding
Funding for this research was provided by:
Avicenna-Studienwerk e.V. (Stipend for HHH)
Medical Faculty of Ruhr-University Bochum (F981-R2020)
Medical Faculty of Ruhr-University Bochum (Research funds from the faculty for the Department of Neurology)
Medical Faculty of Ruhr-University Bochum (F981-R2020)
Katholisches Klinikum Bochum gGmbh
- License Information
-
More Information
Article History
Received: 17 November 2023
Accepted: 26 July 2024
First Online: 1 August 2024
Competing interests
: The authors declare the following potential conflicts of interest, all not related to the content of this manuscript: HHH, AB, NH, SO, SD, XP have nothing to disclose. RG serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, Merck and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis. SF has received speaker’s and/or scientific board honoraria from Biogen, BMS, Celgene, Janssen, Merck, Neuraxpharm, Novartis and Roche and grant support from Ruhr-University Bochum, DFG, DMSG, Stiftung für therapeutische Forschung, Lead Discovery Center GmbH and Novartis.
